About OnKure Therapeutics, Inc.
https://onkuretherapeutics.comOnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.
CEO
Nicholas A. Saccomano
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-10-07 | Reverse | 1:10 |
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
ACORN CAPITAL ADVISORS, LLC
Shares:2.84M
Value:$9.06M
CITADEL ADVISORS LLC
Shares:1.02M
Value:$3.24M
SHAY CAPITAL LLC
Shares:917.93K
Value:$2.93M
Summary
Showing Top 3 of 43
About OnKure Therapeutics, Inc.
https://onkuretherapeutics.comOnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $15.5M ▼ | $-14.7M ▲ | 0% | $-1.09 ▲ | $-14.49M ▲ |
| Q2-2025 | $0 | $16.32M ▼ | $-15.39M ▲ | 0% | $-1.14 ▲ | $-15.18M ▲ |
| Q1-2025 | $0 | $17M ▼ | $-15.93M ▲ | 0% | $-1.19 ▲ | $-16.79M ▲ |
| Q4-2024 | $0 | $33.8M ▲ | $-35.19M ▼ | 0% | $-2.64 ▼ | $-31.16M ▼ |
| Q3-2024 | $0 | $4.66M | $-3.69M | 0% | $-0.28 | $-3.68M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $70.33M ▼ | $72.83M ▼ | $6.41M ▼ | $66.43M ▼ |
| Q2-2025 | $83.37M ▼ | $86.07M ▼ | $7.9M ▼ | $78.17M ▼ |
| Q1-2025 | $96.66M ▼ | $99.88M ▼ | $9.23M ▼ | $90.65M ▼ |
| Q4-2024 | $110.76M ▲ | $114.91M ▲ | $11.08M ▲ | $103.83M ▲ |
| Q3-2024 | $76.67M | $77.64M | $3.63M | $74.02M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-14.7M ▲ | $-13.04M ▲ | $-6K ▲ | $0 | $-13.04M ▲ | $-13.04M ▲ |
| Q2-2025 | $-15.39M ▲ | $-13.27M ▲ | $-13K ▲ | $0 ▲ | $-13.29M ▲ | $-13.29M ▲ |
| Q1-2025 | $-15.93M ▲ | $-14.01M ▲ | $-18K ▲ | $-77K ▼ | $-14.1M ▼ | $-14.02M ▲ |
| Q4-2024 | $-35.19M ▼ | $-21.02M ▼ | $-45.38M ▼ | $114.22M ▲ | $50.07M ▲ | $-21.07M ▼ |
| Q3-2024 | $-11.56M | $-10.66M | $-18K | $5K | $-10.67M | $-10.68M |
CEO
Nicholas A. Saccomano
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-10-07 | Reverse | 1:10 |
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
ACORN CAPITAL ADVISORS, LLC
Shares:2.84M
Value:$9.06M
CITADEL ADVISORS LLC
Shares:1.02M
Value:$3.24M
SHAY CAPITAL LLC
Shares:917.93K
Value:$2.93M
Summary
Showing Top 3 of 43